Skip to main content

Advertisement

Table 1 The characteristics of patients of the two treatment groups (EBRT + NBT and 3D-CRT) and the univariate analysis of the clinical outcome

From: A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer

Characteristics Total (%) EBRT + NBT (%) 3D-CRT (%) P value* 5y OS (%) P value 5y LC (%) P value
Gender   <0.0001   0.174   0.312
 Male 583 (66.0) 324 (59.4) 259 (76.4)   24.5   44.7  
 Female 301 (34.0) 221 (40.6) 80 (23.6)   30.8   51.9  
Age (years)   0.003   0.291   0.591
 ≤65 426 (48.2) 284 (52.1) 142 (41.9)   29.9   48.3  
 >65 458 (51.8) 261 (47.9) 197 (58.1)   23.5   46.4  
Tumor length   0.220   <0.0001   <0.0001
 ≤5 cm 409 (46.3) 261 (47.9) 148 (43.7)   31.0   52.4  
 >5 cm 475 (53.7) 284 (52.1) 191 (56.3)   22.9   42.4  
Tumor location   <0.0001   0.233   0.581
 Upper 329 (37.2) 174 (31.9) 155 (45.7)   26.9   49.2  
 Middle 442 (50.0) 309 (56.7) 133 (39.2)   27.8   45.6  
 Lower 113 (12.8) 62 (11.4) 51 (15.0)   20.9   46.4  
T stage   0.006   <0.0001   <0.0001
 T1 32 (3.6) 20 (3.7) 12 (3.5)   64.1   73.1  
 T2 163 (18.4) 107 (19.6) 56 (16.5)   32.9   51.7  
 T3 305 (34.5) 164 (30.1) 141 (41.6)   31.2   53.9  
 T4 384 (43.4) 254 (46.6) 130 (38.3)   17.6   37.7  
N stage   <0.0001     <0.0001
 N0 461 (52.1) 338 (62.0) 123 (36.3)   32.6   53.2  
 N1 423 (47.9) 207 (38.0) 216 (63.7)   20.2   40.0  
AJCC stage   <0.0001   <0.0001   <0.0001
 I 28 (3.2) 20(3.7) 8 (2.4)   72.3   74.5  
 IIa 280 (31.7) 195 (35.8) 85 (25.1)   36.0   56.6  
 IIb 55 (6.2) 22 (4.0) 33 (9.7)   29.3   35.2  
 III 521 (58.9) 308 (56.5) 213 (62.8)   19.2   41.1  
Radiation dose   <0.0001   0.263   0.658
 ≤60Gy 321 (36.3) 91 (16.7) 230 (67.8)   22.9   44.7  
 >60Gy 563 (63.7) 454 (83.3) 109 (32.2)   29.0   48.6  
  1. Abbreviations: EBRT + NBT external beam radiotherapy plus neutron brachytherapy; 3D-CRT three dimensional conform radiotherapy
  2. P value*: the P values corresponding to the log-rank test between the two treatment groups (EBRT + NBT and 3D-CRT)